Navigation Links
When Prescribing New Drugs for Crohn's Disease or Ulcerative Colitis, Surveyed EU5 Gastroenterologists Will Prioritize Remission Rates Over Cost and Reimbursement Hurdles

BURLINGTON, Mass., Dec. 16, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, when considering the most important attributes for prescribing emerging therapies for Crohn's disease (CD) and ulcerative colitis (UC), instead of using leading anti-TNF agents (Merck's Remicade and AbbVie's Humira), 44 to 70 percent of surveyed gastroenterologists cite higher rates of induction and maintenance of remission as the primary driver. In addition, 12 to 34 percent of surveyed gastroenterologists identify superior efficacy over anti-TNFs in head-to-head trials as another driver, while only up to 10 percent of physicians list the nonclinical factors, lower cost burden and fewer reimbursement restrictions.

(Logo: )

Lack of initial efficacy and waning efficacy over time are also the primary reasons currently driving discontinuation of the anti-TNF-alpha agents, according to survey respondents. While the emerging biologics vedolizumab (Takeda) for CD and UC and Stelara (Janssen) for CD show at least comparable efficacy at maintenance of remission when indirectly compared to Remicade, in the absence of head-to-head comparative data that show superiority over this agent or other anti-TNFs, vedolizumab and Stelarawill face challenges in gaining preferential uptake.

The European Physician & Payer Forum report entitled Crohn's Disease and Ulcerative Colitis in the EU5: How Will Pricing and Reimbursement Decisions for Novel Biologics and Oral Immunomodulators Impact Prescribing? also emphasizes the importance of direct comparative data for favorable pricing and reimbursement of emerging biologics. As more rigorous health technology assessments that focus on added benefit are introduced across the EU5, proven superiority over appropriate comparators is increasingly required for optimal pricing and reimbursement. For example, based on indirect comparison with Remicade, interviewed payers believe that the clinical profile of vedolizumab in CD or UC is not strong enough to justify reimbursement before anti-TNFs if priced at a 25 percent or greater premium.

"While EU5 gastroenterologists expect vedolizumab to encroach on their use of anti-TNFs by the end of 2017, in the absence of a head-to-head trial showing evidence of superior efficacy that may justify use before anti-TNFs and with a potentially higher price, anti-TNFs will continue to dominate patient share," said Decision Resources Analyst Kathrina Quinn, Ph.D. "These data also reflect the expected entry of the more favorably priced biosimilar infliximab, which will bolster drug class share. At least 74 percent of surveyed gastroenterologists expect to prescribe biosimilar versions of Remicade within a year of availability for either CD or UC, but many are willing to do so under certain conditions only, such as if an acceptable safety and/or immunogenicity profile is shown."  

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Nations Largest Medical Society Says Doctors Should Check Drug Database Before Prescribing Addictive Drugs, Says Consumer Watchdog Campaign
2. New Study Evaluates Psychotropic Prescribing For Persons with Intellectual Disabilities, Other Psychiatric Disorders
3. Contrasting Reimbursement Environments Result in Different Prescribing Patterns for Premium-Priced Therapies in China and South Korea
4. U.S. Physician Prescribing Behavior Impacted by Health Insurance Exchanges and Accountable Care Organizations
5. Lack of Formulary Access Tops List of Limitations Primary Care Physicians Face With e-Prescribing Systems, Says New Research Report from SciMedica Group MR&C
6. Paul Kauffman of Accident Fund to Present on Identifying Risky Opioid Prescribing Patterns at 99th Annual International Association of Industrial Accident Boards & Commissions Conference
7. Differences Over Pathways Developed by Oncologists and MCOs May Create Conflict Over Prescribing Decisions in Early-Line Treatment
8. Abuse-Deterrent Formulations of Purdues OxyContin and Endo Pharmaceuticals Opana ER Have Not Increased PCPs Comfort When Prescribing These Products for Chronic Pain
9. U.S. and European Rheumatologists Agree That a Therapys Induction of Remission is One of the Attributes That Most Influences Their Prescribing Decisions in Rheumatoid Arthritis
10. Approval for One Neuropathic Pain Indication is Sufficient to Support Physician Prescribing and Payer Reimbursement Across Multiple Neuropathic Pain Populations
11. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
Post Your Comments:
(Date:11/26/2015)... 26, 2015 ... "Radioimmunoassay Market by Type (Reagents & ... Academics, Clinical Diagnostic Labs), Application (Research, Clinical ... 2020" report to their offering. ... addition of the "Radioimmunoassay Market by ...
(Date:11/25/2015)... ) ... "Global Brain Monitoring Devices Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... Somu Sivaramakrishnan announced today that ... Somu now offers travelers, value and care based Travel Services, including exclusive pricing ... well as, cabin upgrades and special amenities such as, shore excursions, discounted fares, ...
(Date:11/26/2015)... , ... November 26, 2015 , ... Jobs in hospital ... healthcare professionals and offered by healthcare staffing agency Aureus Medical Group . ... month of October 2015 among those searching for healthcare jobs through the company’s website, ...
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, Inc., the first ... annual Employee Benefits Conference. The Employee Benefits Conference was hosted by the International ... November 11th, 2015. The conference was held at the Hawaii Convention Center in ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... mental health and wellness consultation, has collaborated with Women’s Web – an ... reader’s queries on topics on mental and emotional well-being relationship, life balance, ...
(Date:11/25/2015)... ... November 25, 2015 , ... Additional ... those found on mammography, according to a study published online in the journal ... seen on mammography may necessitate a change in treatment. , Breast MRI is ...
Breaking Medicine News(10 mins):